Brief: UroGen Announces Positive Interim Data From Phase 2B Study Of UGN-102 In Patients With Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer
03/04/2020 13:34
April 3 (Reuters) - Urogen Pharma Ltd UR8.F :
* UROGEN ANNOUNCES POSITIVE INTERIM DATA FROM PHASE 2B STUDY
OF
UGN-102 IN PATIENTS WITH LOW-GRADE INTERMEDIATE RISK NON-MUSCLE
INVASIVE BLADDER CANCER
* UROGEN PHARMA LTD - COMPLETE RESPONSE RATE OF 65% AT
THREE
MONTHS
Source text for Eikon: ID:nBw5w5N0ja
Further company coverage: UR8.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on UroGen Pharma
See all newsBrief: Urogen Submits NDA For Ugn-103, An Investigational Treatment Of Recurrent Lg-Ir-Nmibc
Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Brief: Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Urogen Announces Refinanced Term Loan Agreement With Pharmakon Advisors